Introduction
============

Hypertension is a progressive disease that affects more than 1 billion people around the world ([@b7-vhrm-4-1249]). The risk of developing hypertension increases with age and according to the Framingham Heart Study, even those who have a normal blood pressure (BP) at the age of 55 still carry a lifetime risk for developing hypertension of 90% ([@b35-vhrm-4-1249]). Over time, untreated or poorly controlled hypertension can lead to acute illness such as myocardial infarction and stroke ([@b18-vhrm-4-1249]). Long-standing hypertension is also a risk factor for chronic comorbidities ranging from coronary artery disease to kidney disease to left ventricular hypertrophy and heart failure ([@b18-vhrm-4-1249]; [@b25-vhrm-4-1249]).

American and European guidelines recommend first-line agents for the treatment of hypertension based on the patient's varying "compelling indications" or comorbid disease states ([@b7-vhrm-4-1249]; [@b20-vhrm-4-1249]). Because several classes of medications, such as angiotensin converting enzyme inhibitors (ACEIs) and β-blockers, are appropriate for numerous compelling indications their use predominates other classes that are less universal, such as calcium channel blockers (CCBs). Dihydropyridine CCBs have been determined to be appropriate for first-line therapy in patients with hypertension, particularly in those with left ventricular hypertrophy, asymptomatic atherosclerosis, angina pectoris, permanent atrial fibrillation, peripheral artery disease, isolated systolic hypertension, metabolic syndrome, and pregnancy ([@b18-vhrm-4-1249]; [@b3-vhrm-4-1249]; [@b28-vhrm-4-1249]; [@b20-vhrm-4-1249]). Non-dihydropyridine CCBs are also appropriate for use in patients with angina pectoris and carotid atherosclerosis ([@b20-vhrm-4-1249]). One trial found no significant difference between ACEIs and CCBs in terms of total number of coronary events, cardiovascular mortality, total mortality, or coronary heart disease ([@b3-vhrm-4-1249]). Extended-release calcium channel blockers are recommended as an appropriate first-line agent for the treatment of ischemic heart disease, particularly in patients with stable angina pectoris ([@b7-vhrm-4-1249]). Other potential indications include those patients at an increased risk for coronary disease and diabetes, where CCBs have been shown to reduce the incidence of cardiovascular disease and stroke, Raynaud's syndrome, and specific arrhythmias ([@b7-vhrm-4-1249]). CCBs have not been shown to prevent the incidence of heart failure ([@b3-vhrm-4-1249]). African American patients tend to have an increased response to CCBs and diuretics as compared to other antihypertensives such as ACEIs, angiotensin receptor blockers (ARBs), and β-blockers ([@b31-vhrm-4-1249]). It is important to note that not all CCBs are alike and in fact this class is more heterogenous than most other classes of antihypertensives therefore each agent needs to be considered individually.

Nifedipine is a dihydropyridine calcium channel blocker, the short acting formulation of which has been associated with reflex sympathetic nervous system (SNS) activation leading to flushing, tachycardia, worsening myocardial ischemia, and cerebrovascular ischemia; therefore only longer acting formulations should be used ([@b14-vhrm-4-1249]). Numerous extended-release formulations are available worldwide and have been shown to be equally efficacious as compared to other antihypertensives such as ARBs, β-blockers, and diuretics in the management of hypertension ([@b11-vhrm-4-1249]; [@b36-vhrm-4-1249]; [@b4-vhrm-4-1249]). This review focuses on the extended-release formulations of nifedipine and their role in the treatment of patients with hypertension.

Pharmacology
============

Nifedipine exerts its effect in hypertension, as well as angina, by acting as an arterial vasodilator. Calcium ions regulate smooth muscle contractions contributing to inotropic and chronotropic activity in the heart ([@b25-vhrm-4-1249]). The L-type channels in vascular smooth muscle permit the entrance of calcium ions which potentiates a contraction ([@b1-vhrm-4-1249]). Dihidropyridine CCBs such as nifedipine bind to the L-type channel in arterial tissue, particularly coronary arteries, preventing the influx of calcium ions which allows for vasodilation, thus increasing myocardial oxygen supply ([@b2-vhrm-4-1249]; [@b24-vhrm-4-1249]). Myocardial oxygen demand is reduced with the decrease in peripheral vascular resistance ([@b2-vhrm-4-1249]). CCBs are also responsible for a decrease in afterload, illustrated by a decrease in systolic BP (SBP) ([@b2-vhrm-4-1249]). The decrease in BP depends on the baseline value such that patients with a higher BP will experience a more significant reduction ([@b12-vhrm-4-1249]). Several studies have also shown a decrease in the development of new atherosclerotic lesions with the use of dihydropyridine CCBs which is attributed to their vascular protective characteristics ([@b37-vhrm-4-1249]).

Pharmacokinetics
================

Nifedipine displays zero-order kinetics across the dosing range from 30 mg to 180 mg with an estimated elimination half-life of 1.7 hours. This is significant considering the effect on heart rate (HR) and BP corresponds to plasma drug concentration ([@b29-vhrm-4-1249]; [@b24-vhrm-4-1249]). Renal impairment does not affect the half-life of nifedipine unless it is severe (CrCl \< 25 mL/minute), in which case the half-life is extended to approximately 3.8 hours ([@b6-vhrm-4-1249]). Sixty to eighty percent of the dose is excreted as an inactive metabolite in the urine ([@b24-vhrm-4-1249]). Nifedipine is hepatically metabolized and is 92% to 98% protein bound. Due to significant first-pass metabolism nifedipine's bioavailability is between 45%--68% ([@b6-vhrm-4-1249]; [@b24-vhrm-4-1249]). Chronic liver disease may prolong the disposition half-life and increase the bioavailability ([@b24-vhrm-4-1249]).

Extended-release formulations of nifedipine are desired in order to prolong the therapeutic effect and prevent reflex SNS activation. The nifedipine gastrointestinal therapeutic system (GITS) is one of the more prevalent extended-release formulations. There are two layers in the system; the top contains drug and osmotic agent and the bottom containing an osmotic driving agent only ([@b6-vhrm-4-1249]; [@b29-vhrm-4-1249]). Both layers take water in across the membrane via osmosis creating a suspension within the top layer ([@b29-vhrm-4-1249]). This suspension is driven out through a pre-drilled hole as the osmotic layer expands ([@b29-vhrm-4-1249]). The rate at which drug disperses corresponds to the rate at which water enters the system; generally speaking, drug is released consistently over 16 to 18 hours with a bioavailability between 75% and 85% at steady state ([@b6-vhrm-4-1249]; [@b29-vhrm-4-1249]). The diameter of the pre-drilled opening limits the rate at which drug exits the system, thus preventing a dose-dumping effect ([@b29-vhrm-4-1249]; [@b6-vhrm-4-1249]). This process does not depend upon pH or intestinal motility, therefore drug distribution out of the system does not vary with gastrointestinal contents or function ([@b29-vhrm-4-1249]). The exception occurs when retention time in the gut is extensively minimized to less than 24 hours, such as with short bowel syndrome, in which case the full dose is not absorbed ([@b6-vhrm-4-1249]).

Studies have been conducted that compare various nifedipine formulations in an attempt to establish if there is a clinically significant benefit of one extended-release formulation over another. It has been established that the reflex activation of the SNS correlates with the rate of increase in plasma drug levels. Thus it is hypothesized that a more gradual rise in drug concentrations should decrease SNS activation, in turn reducing adverse events associated with short acting nifedipine ([@b9-vhrm-4-1249]). One such trial of 25 patients compared nifedipine GITS 60 mg once daily (Adalat XL^®^; Bayer) to either nifedipine prolonged action 20 mg twice daily (Adalat PA^®^) or two 10 mg nifedipine capsules every 8 hours (Adalat^®^) under fasting conditions ([@b34-vhrm-4-1249]). This trial failed to demonstrate a relationship between peak plasma drug concentrations with the three formulations and BP reduction, which opposes the findings of previous studies ([@b34-vhrm-4-1249]). The author concluded that patients should not be switched between formulations because although there was no correlation with BP, peak plasma drug concentrations may correspond to reflex activation of the SNS, thus inducing cardiovascular events ([@b34-vhrm-4-1249]).

Due to the high incidence of tachycardia and vasodilatory symptoms associated with short-acting nifedipine, emphasis has been placed on determining the effect of extended-release nifedipine on catecholamine levels and corresponding HR and BP values. It has been suggested that a higher incidence of cardiovascular events associated with nifedipine may be due to reflex activation of the SNS ([@b5-vhrm-4-1249]). As long-acting nifedipine formulations became more readily available attention was placed on the occurrence of reflex SNS activation in correlation with plasma drug concentration ([@b5-vhrm-4-1249]). One study compared the acute and chronic effects of nifedipine on HR, BP, norepinephrine (NE), and epinephrine levels ([@b5-vhrm-4-1249]). Sixtyfive patients with mild to moderate hypertension were treated with nifedipine retard 10 mg twice daily, nifedipine GITS 30 mg daily, or amlodipine 5 mg daily for 2 weeks with the option to double treatment doses for the last 4 weeks if BP was not controlled ([@b5-vhrm-4-1249]). Acute treatment effects were assessed just before and after the first treatment dose whereas chronic effects were analyzed after 6 weeks of therapy ([@b5-vhrm-4-1249]). All three treatment arms significantly reduced SBP and diastolic BP (DBP) at 2 weeks through the end of the treatment period, but only amlodipine was found to increase HR significantly by the end of therapy (75 ± 2 beats per min to 81 ± 2.3 beats per minute, p \< 0.05). While all three treatments equally reduced BP, their effects on norepinephrine levels were not equivalent. Plasma norepinephrine levels increased significantly with nifedipine retard, both acutely and chronically, reaching their peak 3 hours after drug administration ([@b5-vhrm-4-1249]). Similarly, chronic amlodipine therapy increased plasma levels of norepinephrine by 50% compared to baseline ([@b5-vhrm-4-1249]). Chronic therapy with nifedipine GITS decreased plasma NE levels significantly 6 hours after the dose and this effect was maintained throughout the dosing interval ([@b5-vhrm-4-1249]). The nifedipine GITS formulation was associated with a more gradual decrease in BP without an increase in NE, potentially due to the fact that plasma drug levels were lower than those obtained by nifedipine retard ([@b5-vhrm-4-1249]). This study demonstrated a relationship between an increase in plasma norepinephrine, the rate of increase in drug concentration, and a subsequent and sudden drop in BP ([@b5-vhrm-4-1249]).

Another, 48-week study compared nifedipine GITS to lercanidipine, a third generation CCB whose lipophilicity allows for a longer half-life ([@b9-vhrm-4-1249]). Patients were randomized to 10 mg of lercanidipine or 30 mg of nifedipine GITS for 4 weeks, after which the doses could be doubled if the patient's DBP was \> 90 mmHg ([@b9-vhrm-4-1249]). BP, HR, and NE levels were evaluated throughout the study period ([@b9-vhrm-4-1249]). Compared to placebo, both treatments effectively decreased BP (p \< 0.001 for both arms) with no significant change in HR ([@b9-vhrm-4-1249]). There was a significant increase in NE concentrations at 4 weeks in both treatment arms ([@b9-vhrm-4-1249]). Only nifedipine GITS significantly increased NE levels at 48 weeks compared to baseline drug concentrations reached their peak and 12 hours after the dose (p \< 0.05 at both times) ([@b9-vhrm-4-1249]). Because HR was not affected despite changes in NE, this suggests the effects of nifedipine GITS on the SNS might be selective for peripheral and not cardiac nerves ([@b9-vhrm-4-1249]). Just as BP control is a predictor for cardiovascular events, norepinephrine levels are a similar surrogate marker; therefore, because both agents decreased BP effectively, little can be extrapolated from the variation in effect on norepinephrine.

Clinical trials
===============

Nifedipine has been compared head-to-head with several other antihypertensives, particularly when the GITS formulation was released. With a diminished concern for reflex SNS activation nifedipine had the potential to play a larger role in the management of hypertension. In a 10-week, multi-center, double-blind study of 102 participants, patients received nifedipine GITS 30 or 60 mg daily, hydrochlorothiazide (HCTZ) 25 or 50 mg daily, or placebo ([@b13-vhrm-4-1249]). The majority of patients in the active treatment arms finished the study on 50 mg of HCTZ or 60 mg of nifedipine GITS ([@b13-vhrm-4-1249]). Both treatments were significantly better than placebo in decreasing SBP and DBP with 71% of the HCTZ group and 67% of the nifedipine group achieving a sitting DBP \< 90 mmHg ([@b13-vhrm-4-1249]). The authors concluded that nifedipine GITS monotherapy decreases BP with efficacy similar to that of HCTZ ([@b13-vhrm-4-1249]).

In another double-blind study, patients received nifedipine GITS or sustained-release propranolol for 8 weeks, both of which could be titrated to an optimal dose if the DBP remained \>90 mmHg ([@b12-vhrm-4-1249]). The main objective of the trial was to evaluate the change in BP from baseline as well as the proportion of patients whose BP was decreased to goal ([@b12-vhrm-4-1249]). The majority of patients in the nifedipine and propranolol groups ended the trial on 90 mg and 240 mg daily, respectively ([@b12-vhrm-4-1249]). In this study, sitting SBP was decreased a mean of 15.9 mmHg in the nifedipine group compared to 5.7 mmHg in the propranolol group (p \< 0.001) ([@b12-vhrm-4-1249]); sitting DBP was reduced by a mean of 10 mmHg in the nifedipine arm versus 6.1 mmHg in the propranolol group (p \< 0.018) ([@b12-vhrm-4-1249]). Standing SBP was also reduced to a greater extent in the nifedipine group (p \< 0.005) ([@b12-vhrm-4-1249]). The proportion of patients receiving nifedipine who achieved a goal decrease in sitting and standing BP was 61% and 52%, respectively, as compared to 25% and 28% in the propranolol group ([@b12-vhrm-4-1249]). This study showed nifedipine GITS to be more efficacious than sustained-release propranolol in reducing sitting SBP and DBP, as well as standing SBP ([@b12-vhrm-4-1249]).

Nifedipine has also been compared to other dihydropyridine CCBs, such as amlodipine. One particular study randomized patients to daily nifedipine GITS 30 mg or amlodipine 5 mg for 21 weeks to assess the effect on DBP as well as quality of life ([@b30-vhrm-4-1249]). The main objectives of the study were to evaluate the change in SBP and DBP as well as the change in health-related quality of life. Results pertaining to quality of life will be discussed later (see Tolerability). The study showed no significant difference between treatment arms with respect to SBP or DBP ([@b30-vhrm-4-1249]). The mean decrease in SBP was 18.8 mmHg with nifedipine and 19.7 with amlodipine while the mean reduction in DBP was 15.5 with nifedipine and 15.7 with amlodipine (p \> 0.55 for SBP and DBP) ([@b30-vhrm-4-1249]).

As mentioned previously, ACEIs are recommended as first-line antihypertensives in patients with varying comorbid conditions. One study compared the efficacy of once-daily nifedipine GITS 30 to 60 mg with that of enalapril 5 to 10 mg daily over the course of 8 weeks by measuring BP and HR at each visit as well as utilizing ambulatory BP monitoring (ABPM) ([@b26-vhrm-4-1249]). At the end of the treatment period DBP and SBP were significantly decreased from baseline in both groups (p \< 0.001 for DBP in both treatments) ([@b26-vhrm-4-1249]). More patients in the nifedipine group were maintained on a low-dose regimen compared to the enalapril group (p \< 0.05) ([@b26-vhrm-4-1249]). Twenty-four hour SBP decreased from 141 ± 15 mmHg to 134 ± 14 mmHg in the nifedipine group compared to enalapril where SBP decreased from 140 ± 15 mmHg to 131 ± 15 mmHg ([@b26-vhrm-4-1249]). DBP was 86 ± 9 mmHg for both groups at baseline and decreased to 82 ± 9 mmHg in the nifedipine group and 80 ± 8 mmHg in the enalapril group ([@b26-vhrm-4-1249]). This trial demonstrated that nifedipine GITS and enalapril are similarly efficacious for the treatment of hypertension ([@b26-vhrm-4-1249]).

ARBs are a standard first-line therapy and alternative to ACEIs in the treatment of hypertension, particularly in those patients with compelling indications such as diabetes, chronic kidney disease, and heart failure ([@b7-vhrm-4-1249]). One trial sought to compare the effects of nifedipine GITS 30 mg, 60 mg, or 90 mg with losartan 50 mg monotherapy or with HCTZ 12.5 mg or 25 mg on mean sitting DBP after 12 weeks ([@b36-vhrm-4-1249]). Two hundred twenty-three patients were treated and decreases in BP were similar in both groups ([@b36-vhrm-4-1249]). Those patients who had a higher baseline DBP (106--115 mmHg) showed a significantly greater benefit for sitting DBP at the end of therapy when treated with losartan compared with nifedipine GITS (--16.2 ± 7.1 mmHg, p = 0.03) ([@b36-vhrm-4-1249]). There was no significant difference in SBP, the percentage of patients who had a sitting DBP \< 90 mmHg at the end of treatment, HR, quality of life, or adverse events between the two groups ([@b36-vhrm-4-1249]). The authors concluded that losartan is similarly efficacious to nifedipine GITS in the treatment of hypertension but with greater tolerability, particularly with respect to edema ([@b36-vhrm-4-1249]). Similar results were found in an open-label study comparing nifedipine GITS to telmisartan in combination with HCTZ ([@b10-vhrm-4-1249]).

It has been well demonstrated that short-acting nifedipine can cause reflex sympathetic activation. What has been less studied is how extended-release nifedipine affects the SNS. Several trials have evaluated the effects of extended-release nifedipine on HR and BP throughout the dosing interval. A study by Wenzel and colleagues evaluated the effect of nifedipine GITS 60 mg on muscle sympathetic nervous activity (MSA) as compared to short-acting nifedipine 5 mg and 10 mg or placebo in normotensive patients ([@b37-vhrm-4-1249]). MSA, measured in change of bursts per minute, increased significantly following 10 mg of short-acting nifedipine and 60 mg nifedipine GITS (p \< 0.05 vs placebo). There was no significant change in HR in the nifedipine GITS group compared to baseline; however during the cold pressor test HR increased significantly (p \< 0.05). SBP did not change but DBP increased significantly following the administration of nifedipine GITS (p \< 0.05). Because plasma NE levels are a predictor of mortality in heart failure patients and elevated levels may be harmful in patients with hypertension, concentrations were evaluated at various time points in this trial. Concentrations increased significantly 150 minutes after drug administration (p \< 0.05) but plasma epinephrine levels did not change significantly. Plasma endothelin levels were significantly elevated in the nifedipine GITS group 6 hours after drug intake (p \< 0.05). This trial showed that nifedipine stimulates peripheral sympathetic nerve activity, despite the formulation of the drug; however there was no change in cardiac sympathetic activity. It is proposed that because extended-release nifedipine allows for a more controlled onset of vasodilation, the SNS is selectively activated in the periphery leading to an increase in MSA while the cardiac sympathetic system is not affected as demonstrated by the lack of change in HR ([@b37-vhrm-4-1249]). A similar theory has been proposed in previously discussed studies ([@b9-vhrm-4-1249]).

Other cardiovascular pathways are implicated in the progression of hypertension and nifedipine may have benefits beyond its vasodilatory effects. There are several mechanistic factors involving granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-α (TNF-α). GM-CSF and TNF-α are increased in patients with hypertension and this may contribute to an increased risk for atherosclerosis ([@b27-vhrm-4-1249]). These details have just recently been elucidated in a trial that evaluated the effects of CCBs on superoxide (O~2~^−^) liberation from neutrophils. O~2~^−^ release is mediated by GM-CSF and TNF-α and studies have shown that some CCBs may inhibit this process ([@b27-vhrm-4-1249]). O~2~^−^ release mediated by TNF-α was suppressed significantly by nifedipine (p \< 0.01) ([@b27-vhrm-4-1249]). The authors of this trial suggest that some CCBs may have a role in the prevention of atherosclerosis via the suppression of neutrophil activation ([@b27-vhrm-4-1249]). One should keep in mind that this study looked at several surrogate endpoints for atherosclerosis in vitro, therefore the clinical significance is unknown. As this is a relatively new area of study more data are needed before the effects of nifedipine on atherosclerosis can be substantiated.

All of these trials share similar limitations in that their duration of treatment and follow-up is relatively short, ranging from 8 to 48 weeks ([@b12-vhrm-4-1249]; [@b26-vhrm-4-1249]; [@b9-vhrm-4-1249]). The mean age of patients in the previously mentioned studies ranges between the sixth and seventh decades of life; therefore most of these patients can expect to live another 20 to 30 years ([@b20-vhrm-4-1249]). Patients were followed for just a few months despite the fact that complications from poorly controlled hypertension take years to manifest. Ultimately it is the occurrence of an event, whether fatal or non-fatal, that is of interest, not the surrogate endpoints such as changes in BP from baseline. While it is well understood that BP is a strong predictor of cardiovascular events, the duration of follow up may not be adequate to determine a truly beneficial effect, or lack thereof.

A prospective, double-blind trial by Brown and colleagues assessed morbidity and mortality in European and Israeli patients who had hypertension in addition to a cardiovascular risk factor such as hypercholesterolemia, CHD, peripheral vascular disease, left ventricular hypertrophy, or a family history of myocardial infarction ([@b4-vhrm-4-1249]). The primary endpoint of the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT) trial was the composite of death from a cardiovascular or cerebrovascular cause, non-fatal stroke, myocardial infarction, and heart failure. Patients were randomized to receive nifedipine GITS 30 mg or co-amilozide (HCTZ 25 mg/amiloride 2.5 mg) daily ([@b4-vhrm-4-1249]). The primary outcome was reported in 6.3% of patients in the nifedipine group compared to 5.8% in the co-amilozide group (p = 0.34). There was no significant difference in event rates between groups. Significantly greater number of patients experienced a fatal myocardial infarction or non-fatal heart failure in the nifedipine group (0.5% vs 0.2%, p = 0.017 and 0.8% vs 0.3%, p = 0.028, respectively). The authors concluded that both agents were equally efficacious in preventing cardiovascular and cerebrovascular complications ([@b4-vhrm-4-1249]).

One subanalysis of the INSIGHT data was performed to evaluate ambulatory BP values before and after treatment ([@b21-vhrm-4-1249]). Office and 24-hour average SBP, DBP, and pulse pressure were significantly reduced by both treatments. The authors therefore concluded that nifedipine and diuretics offer similar protection against cardiovascular events ([@b21-vhrm-4-1249]). Another subanalysis evaluated outcomes in patients with isolated systolic hypertension (ISH) ([@b22-vhrm-4-1249]). Primary outcomes occurred in 6% of patients in the nifedipine arm compared to 6.6% in the group receiving diuretics (p = 0.67) ([@b22-vhrm-4-1249]). There were no significant differences in the composite endpoint between those patients with ISH compared to non-ISH patients ([@b22-vhrm-4-1249]). According to logistic regression analyses ISH was not found to be a predictor of the composite primary outcomes after adjusting for baseline characteristics ([@b22-vhrm-4-1249]). The study's authors determined that nifedipine GITS and diuretics are equally efficacious in the treatment of patients with ISH ([@b22-vhrm-4-1249]).

Chronotherapy
=============

It has been well documented that HR and BP vary throughout the day in a circadian pattern and one hypothesis suggests the daily increases in HR and BP correspond to a recurrent rise in norepinephrine. This theory is supported by the fact that the incidence of ischemic events such as myocardial infarctions and stroke is highest in the morning. Numerous studies have evaluated the correlation between the time of day extended-release nifedipine is administered with NE levels and subsequent cardiovascular events ([@b38-vhrm-4-1249]; [@b16-vhrm-4-1249]; [@b15-vhrm-4-1249]).

One double-blind, randomized, parallel-group trial of 557 patients compared controlled-onset extended-release (COER) verapamil 180 mg taken at bedtime with nifedipine GITS 30 mg taken in the morning for a maximum of 10 weeks ([@b38-vhrm-4-1249]). Doses were increased in a step-wise fashion to a goal SBP \< 140 mmHg and DBP \< 90 mmHg ([@b38-vhrm-4-1249]). The mean doses of nifedipine GITS and COER-verapamil at the end of the trial were 64 mg and 314 mg, respectively ([@b38-vhrm-4-1249]). The primary efficacy endpoint was the change in BP from baseline following four weeks of a consistent treatment dose ([@b38-vhrm-4-1249]). Therapies were determined to be equal if the mean change from baseline was ≤5 mmHg for SBP and ≤3 mmHg for DBP ([@b38-vhrm-4-1249]). After 10 weeks of treatment there was no significant difference in the mean change of early morning BP between treatment arms. There was a statistically significant difference in early morning HR between the two therapies (p \< 0.001), however the clinical significance of the 4 beats/minute decrease with COER--verapamil as compared to the 2 beats per minute increase with nifedipine GITS is minimal. The rate of rise in BP and HR in the early morning may be one of the more predictive factors in relation to cardiovascular events. This trial demonstrated that both therapies decreased the rate of increase in BP compared to baseline; however nifedipine GITS increased the rate of rise in HR while COER--verapamil significantly decreased the rate of rise in HR (p \< 0.001) ([@b38-vhrm-4-1249]). The early morning HR-SBP product, an index of myocardial oxygen demand, was calculated after 4 and 10 weeks of treatment and showed that COER--verapamil significantly decreased the HR-SBP product compared with nifedipine GITS at 4 and 10 weeks (p \<0.0001 and p = 0.0003, respectively). The greatest extent of lowering by COER--verapamil was between 4:00 AM and 8:00 PM. The largest difference occurred between 6:00 AM and 6:00 PM; the smallest difference was found between 10:00 PM and 4:00 AM. Twenty-four hour ambulatory BP values were also monitored after 4 and 10 weeks of therapy. Recordings demonstrated that 24 hour mean awake and sleep DBP were similar between groups ([@b38-vhrm-4-1249]). This trial attempted to dose nifedipine GITS and COER--verapamil in a manner so that peak drug concentrations would be achieved at the time when BP and HR peak the most rapidly, in the early morning; however there was no significant difference in mean change in morning BP between groups ([@b38-vhrm-4-1249]).

When 30 mg of nifedipine GITS was administered to a small patient population there was no difference in the antihypertensive effect of the medication during the day or at night ([@b16-vhrm-4-1249]). A larger randomized, prospective, open-label trial of 80 patients was then conducted to determine if nifedipine GITS 30 mg or 60 mg given first thing in the morning or at bedtime would have varying effects on BP's circadian pattern over the course of 16 weeks ([@b16-vhrm-4-1249]). BP was measured over 48 hours via ABPM ([@b16-vhrm-4-1249]). The results showed that when nifedipine GITS 30 mg was administered in the morning or at bedtime there was a significant decrease in 24-hour BP compared with baseline (p \< 0.001 for both regimens) ([@b16-vhrm-4-1249]). There was no effect on HR or the circadian pattern of BP, including maximum BP readings throughout the 24-hour interval with either dosing strategy ([@b16-vhrm-4-1249]). In comparison, when 60 mg doses of nifedipine GITS were administered, there was a significant benefit to bedtime dosing in relation to mean 24-hour BP control (p \< 0.001) ([@b16-vhrm-4-1249]). Additionally, patients who received nifedipine GITS at bedtime reported significantly less edema than those who received the drug first thing in the morning (p = 0.026) ([@b16-vhrm-4-1249]). This trial demonstrated that the efficacy of nifedipine GITS is independent of the time of day at which it is administered; however there is a dose-dependent relationship relative to the drug's efficacy and safety with bedtime dosing as compared to early morning administration ([@b16-vhrm-4-1249]).

Another study by some of the same authors as the previously mentioned trial studied patients with hypertension who received nifedipine GITS 30 mg daily either first thing in the morning or at bedtime for eight weeks ([@b15-vhrm-4-1249]). Because the earlier study showed a slight benefit in bedtime dosing, this theory was investigated further using ABPM ([@b15-vhrm-4-1249]). Both SBP and DBP were significantly decreased with bedtime dosing as compared to morning dosing (SBP p = 0.01, DBP p \< 0.001). Morning administration still decreased SBP and DBP significantly compared to baseline values ([@b15-vhrm-4-1249]). Asleep mean SBP, morning surge of SBP, and asleep mean DBP were significantly decreased with bedtime dosing as compared to morning dosing ([@b15-vhrm-4-1249]). The authors of this study concluded that bedtime administration of nifedipine GITS significantly improves ambulatory BP and the prevalence of edema compared to morning dosing ([@b15-vhrm-4-1249]).

Tolerability
============

Extended-release nifedipine appears to be relatively well tolerated, particularly compared with other antihypertensives, because it does not cause depression of the central nervous system or orthostasis ([@b13-vhrm-4-1249]). Common adverse events mentioned in the literature are summarized in [Table 1](#t1-vhrm-4-1249){ref-type="table"}. The most significant adverse effect, edema, is dose related and occurs in 10% to 30% of patients who are receiving 180 mg ([@b24-vhrm-4-1249]). When compared with placebo, headache and edema were more common in the nifedipine extended-release group ([@b24-vhrm-4-1249]).

When nifedipine GITS was compared with COER--verapamil the overall incidence of adverse effects was similar between groups (74% and 68%, respectively) ([@b38-vhrm-4-1249]). Peripheral edema (22% vs 4%, p \< 0.001) and arthralgias (6% vs 2%, p = 0.048) were reported significantly more often in the nifedipine GITS group compared to the COER--verapamil group ([@b38-vhrm-4-1249]). When the GITS formulation was compared to prolonged action and capsule formulations nifedipine GITS was better tolerated with respect to overall adverse events, particularly headache and dizziness ([@b34-vhrm-4-1249]). Only vomiting was more common in the nifedipine GITS arm compared to the other formulations ([@b34-vhrm-4-1249]).

Nifedipine GITS was not as well tolerated as losartan/HCTZ or telmisartan/HCTZ in 12 week studies ([@b36-vhrm-4-1249]; [@b10-vhrm-4-1249]). More patients in the nifedipine group withdrew from the study as compared to the losartan/HCTZ group (19% vs 7%, p = 0.012) ([@b36-vhrm-4-1249]). The most common cause of withdrawal from the study was edema which was significantly more common in the nifedipine group than in those receiving losartan (p = 0.005) ([@b36-vhrm-4-1249]). Ankle edema (13.8% vs 1.6%), headache (5.2% vs 0%), dizziness (1.7% vs 0%), polyuria (1.7% vs 0%), rash erythematosus (1.7% vs 0%), flushing (5.2% vs 0%), palpitation (3.4% vs 0%), and pruritus (1.7% vs 0%) were all more common in the nifedipine group compared to telmisartan--HCTZ ([@b10-vhrm-4-1249]).

Quality of life has been assessed in patients on different dihydropyridine CCBs. One such study investigated the change in quality of life from baseline assessed by the distress of side effects and symptoms of patients receiving either nifedipine GITS 30 mg or amlodipine 5 mg daily ([@b30-vhrm-4-1249]). Patients were assessed using the Higher Symptom Distress Index score where higher scores were indicative of more distress ([@b30-vhrm-4-1249]). Mean quality of life scores were comparable between groups at baseline ([@b30-vhrm-4-1249]). Lower extremity edema (24.2% vs 17.4%), flushing (8.4% vs 10.7%), and headache (12.4% vs 11.2%) were reported in \>5% of patients receiving either nifedipine or amlodipine with no difference between groups ([@b30-vhrm-4-1249]). Fifteen percent of patients receiving nifedipine and 14% of patients receiving amlodipine withdrew before the study's completion due to adverse events ([@b30-vhrm-4-1249]). Patients treated with nifedipine had more distress secondary to shortness of breath, constipation, and tachycardia as opposed to the amlodipine arm which had more distress as a result of thirst and loss of taste ([@b30-vhrm-4-1249]). The Mental/Emotional Health scale improved significantly (p = 0.012) from baseline in patients receiving nifedipine ([@b30-vhrm-4-1249]). The Psychological Distress scale (p = 0.021), Anxiety subscale (p = 0.012), and Depression subscale (p = 0.071) also improved from baseline; however the Depression subscale did not improve significantly ([@b30-vhrm-4-1249]). In the amlodipine group, significant improvements were seen in the Mental/Emotional Health scale (p = 0.038), Psychological Well-Being (p = 0.042), and General Positive Affect subscale (p = 0.037); however there was a significant decrease in the Sexual Symptom Distress score (p = 0.045) ([@b30-vhrm-4-1249]). In terms of the Quality of Life Summary scale, patients receiving nifedipine GITS showed a significant improvement in score (p \< 0.05) while those receiving amlodipine did not change from baseline ([@b30-vhrm-4-1249]). This trial showed that differences in quality of life scores may be attributable to the delivery system.

Conclusion
==========

Clinicians have known for decades that nifedipine is effective at lowering BP. However, its use was curtailed when newer and seemingly safer options were introduced in the form of new drug classes and additional agents within the class of dihydropyridine CCBs. In the years that followed, several classes of antihypertensives were shown to provide a significant reduction in morbidity and mortality in high risk patients; this propelled these classes of drugs to the forefront of hypertension management, specifically ACEIs ([@b39-vhrm-4-1249]), ARBs ([@b8-vhrm-4-1249]), and β-blockers ([@b32-vhrm-4-1249]). Thiazide diuretics have also proven their utility in managing hypertension patients and are widely accepted as a first-line option in patients devoid of a compelling reason to be prescribed another class of antihypertensive ([@b31-vhrm-4-1249]; [@b7-vhrm-4-1249]). Based on the clinical trial data described above, it appears that many of the concerns surrounding the older formulations of nifedipine have been addressed with the GITS formulation. Edema still appears to be relatively common, although timing of dosing may ameliorate this effect. While data are not yet available for long-term mortality benefit of long-acting nifedipine, it is reasonable to consider this medication in situations where other dihydropyridine CCBs would commonly be used (eg, as add-on therapy to improve the patient's likelihood of achieving their BP goal or as initial therapy in patients that need general coronary artery disease prevention and do not have a compelling reason for prescription of another class of antihypertensive). Aggressive use of long-acting nifedipine as a first-line antihypertensive is not supported by clinical data or current practice guidelines. A number of clinical trials evaluating long-acting nifedipine have recently been completed or are ongoing. These include trials evaluating the effects of nifedipine on NE, delivery of nifedipine via osmotically controlled-release oral delivery system (OROS), combination therapy with telmisartan, the effects of nifedipine on proteinuria and BP in patients with diabetes, the effect on renal function decline and efficacy compared with lisinopril. The results of these may provide additional insight into the most appropriate use of long-acting nifedipine.
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###### 

Incidence of adverse events reported in clinical trials

  Adverse event        [@b38-vhrm-4-1249] (mean 64 mg/day)   [@b34-vhrm-4-1249] (60 mg/day)   [@b24-vhrm-4-1249] 180 mg/day   [@b10-vhrm-4-1249] 60 mg/day   [@b36-vhrm-4-1249] 30, 60, or 90 mg/day   [@b30-vhrm-4-1249] 30 mg/day
  -------------------- ------------------------------------- -------------------------------- ------------------------------- ------------------------------ ----------------------------------------- ------------------------------
  Overall incidence    74%                                   24%                                                                                             61%                                       
  Peripheral edema     22%                                                                    10%--30%                        13.8%                          12%                                       24.2%
  Constipation         8%                                                                     3.3%                                                                                                     
  Arthralgia           6%                                                                     \<3%                                                                                                     
  Back pain            1%                                                                     \<1%                                                                                                     
  Headache                                                   21%                              15.8%                           5.2%                           12%                                       12.4%
  Dizziness                                                  3%                               4.1%                            1.7%                           1%                                        
  Nausea                                                     3%                               3.3%                            1.7%                                                                     
  Vomiting                                                   7%                               \<1%                                                                                                     
  Increased alk phos                                                                          5.4%                                                                                                     
  Fatigue                                                                                     5.9%                            --                             2%                                        
  Polyuria                                                                                    \<3%                            1.7%                                                                     
  Rash erythematosus                                                                          \<3%                            1.7%                                                                     
  Flushing                                                                                    \<3%                            5.2%                                                                     8.4%
  Palpitation                                                                                 \<3%                            3.4%                                                                     
  Pruritus                                                                                    \<3%                            1.7%                                                                     
